Background : Lorcaserin is a novel, selective 5-hydroxytryptamine 2C serotonin receptor agonist, approved for the treatment of obesity. Several phase 3 randomized controlled trials (RCTs) trials
Purpose: Drug-induced fever is frequently reported in cancer patients treated with anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1), and stoppage of the offending agent is th
Background: Avacopan, an oral C5a receptor antagonist, has been identified as a promising glucocorticoid-sparing agent in the management of ANCA-associated vasculitis (AAV). Although individual random
